Epidermolysis bullosa (EB) is a group of rare genetic conditions that make skin extremely fragile. Even minor friction, like rubbing against clothing or being picked up, can cause painful blisters and open wounds. It affects roughly 20 out of every million newborns, with an estimated prevalence of about 10 per million people worldwide. The condition ranges from mild blistering limited to the hands and feet to severe, life-threatening forms that affect the skin, internal organs, and virtually every aspect of daily life.
Why the Skin Is So Fragile
Healthy skin holds together because layers of protein act like anchors, binding the outer layer (epidermis) to the deeper layer (dermis). In EB, genetic mutations disrupt the production of one or more of these anchoring proteins. Without them, the connection between skin layers is weak, and even gentle contact causes the layers to separate and form fluid-filled blisters.
Which protein is affected determines which type of EB a person has and how severe it is. Some mutations weaken proteins inside the outermost skin cells themselves. Others affect the glue-like proteins at the junction between skin layers or the collagen fibers that anchor skin to the tissue beneath. The deeper in the skin the separation occurs, the more scarring results.
The Four Major Types
EB is classified into four major types based on where in the skin the blistering happens and which proteins are involved.
Epidermolysis Bullosa Simplex (EBS)
This is the most common form. Blisters form within the outermost skin layer because of defects in structural proteins called keratin 5 and keratin 14, which normally give skin cells their toughness. Roughly 70 to 80 percent of EBS cases involve these two proteins. Most subtypes are inherited in a dominant pattern, meaning a child only needs one copy of the faulty gene (from one parent) to develop the condition. Blistering tends to be milder and often worsens with heat, friction, or physical activity. In many cases, symptoms improve with age.
Junctional EB (JEB)
In JEB, the separation occurs at the junction between the outer and deeper skin layers. The most commonly affected proteins are components of laminin-332, a molecule that helps anchor the two layers together, and type XVII collagen. All subtypes of JEB are inherited in a recessive pattern, meaning both parents must carry a copy of the faulty gene. JEB ranges from mild to extremely severe. The most severe form can be life-threatening in infancy due to widespread blistering and complications like infection and fluid loss.
Dystrophic EB (DEB)
DEB results from mutations in a single gene responsible for producing type VII collagen, the protein that forms anchoring fibrils connecting the skin layers to the tissue underneath. Because the split occurs deeper, wounds heal with significant scarring. DEB comes in both dominant and recessive forms. The recessive form (RDEB) is far more severe and carries the highest risk of serious complications, including progressive scarring that can fuse fingers and toes together over time.
Kindler Syndrome
This rare, recessively inherited form is caused by a defect in a protein involved in cell signaling and attachment. Blistering can occur at multiple levels within the skin, which makes it unique among the EB types. Skin also becomes increasingly sensitive to sunlight with age, and widespread thinning of the skin develops over time.
What Living With EB Looks Like
For people with moderate to severe forms, daily wound care is one of the biggest challenges. Blisters need to be lanced with a sterile needle at multiple points to drain the fluid and prevent them from spreading. The overlying skin is left intact to act as a natural bandage, reducing pain and lowering infection risk. Wounds are then gently cleaned with saline, water, or a mild antiseptic solution, and covered with non-stick dressings. Silicone-coated contact layers and foam dressings are commonly used because they can be removed without tearing new skin.
Dressing changes can take one to several hours daily, depending on the extent of wounds. Caregivers use hand cleansers before each change, and topical antimicrobials are rotated every few weeks to prevent bacterial resistance. Dilute vinegar or bleach baths can help reduce bacterial buildup on the skin. For many families, this routine dominates daily life from infancy onward.
Complications Beyond the Skin
Severe EB, particularly the recessive dystrophic form, is not just a skin condition. The same fragile tissue lines the mouth, esophagus, and other internal surfaces, leading to problems throughout the body.
Esophageal scarring is one of the most common internal complications. Repeated blistering inside the esophagus causes it to narrow over time, making swallowing progressively difficult. An estimated 80 percent or more of people with severe RDEB develop esophageal narrowing before age 25. This can lead to malnutrition, as eating becomes painful and slow.
Chronic wounds create enormous nutritional demands. The body burns extra calories and protein trying to heal constantly, while mouth blisters and esophageal narrowing make it harder to eat enough. Children with EB often struggle with growth and development because they simply cannot take in the calories and nutrients their bodies need. Constipation from reduced food and fluid intake adds to the cycle. Many patients require nutritional supplements or specialized feeding support.
The hands and feet are particularly vulnerable in dystrophic forms. Repeated scarring between the fingers and toes gradually fuses them together, a process called pseudosyndactyly, sometimes described as “mitten deformities.” This progressively limits hand function and independence. Eye involvement, including corneal abrasions from fragile tissue on the eye surface, and chronic anemia from ongoing blood and protein loss through wounds are also common.
Skin Cancer Risk in Severe EB
One of the most serious long-term risks for people with severe recessive dystrophic EB is an aggressive form of skin cancer called squamous cell carcinoma (SCC). Chronic wounds and scarring create an environment where cancerous changes are far more likely, and they happen at a much younger age than in the general population.
Data from the U.S. National EB Registry shows that the cumulative risk of developing a first SCC in severe RDEB is about 7.5 percent by age 20, jumps to 52 percent by age 30, reaches 80 percent by age 45, and climbs to 90 percent by age 55. The youngest reported case occurred in a child of just 6 years old, with a median age of first diagnosis around 29 to 30 years. These cancers tend to be more aggressive than typical skin cancers and are the leading cause of death in adults with severe RDEB.
How EB Is Diagnosed
EB is usually suspected at birth or in early infancy when unexplained blistering appears. Confirming the diagnosis and identifying the specific type requires two complementary tests.
The first is immunofluorescence mapping (IFM), which uses a small skin biopsy and fluorescent markers to pinpoint exactly which layer of skin is separating and which proteins are missing or reduced. This provides a rapid initial diagnosis and helps narrow down the type. The second is genetic testing, which identifies the specific gene mutation responsible. Methods include targeted gene panels that screen all 21 known EB genes, or broader sequencing approaches when the cause is not immediately clear. Together, IFM and genetic testing provide a complete picture at both the protein and DNA levels, which is important for predicting how severe the condition will be and for family planning.
Treatment and Wound Healing
There is no cure for EB, and management has historically focused on protecting the skin, treating wounds, managing pain, and preventing complications. That picture began to change in 2023, when the FDA approved the first gene therapy for dystrophic EB. The treatment, called Vyjuvek, is applied directly to wounds and delivers a working copy of the gene for type VII collagen using a modified virus. It is approved for both adults and children with DEB who carry mutations in the COL7A1 gene. While it does not fix the underlying genetic defect body-wide, it can help individual wounds produce the missing collagen and heal.
Beyond gene therapy, daily life with EB revolves around prevention and careful wound management. Soft clothing, padded surfaces, and avoiding heat and friction help reduce new blisters. Nutritional support, physical therapy to maintain hand function, and regular monitoring for esophageal narrowing, anemia, and skin cancer are all part of ongoing care. For families, the time, cost, and emotional weight of managing severe EB is substantial, often requiring a coordinated team of specialists across dermatology, nutrition, gastroenterology, and rehabilitation.